Hyman J. Zimmerman Hepatotoxicity SOA: Assessing DILI Risk in the Life Cycle of Drugs and Biologics: A Challenge for Regulatory Science

Product not yet rated

Recorded On: 10/23/2017

Drug-induced liver injury (DILI) remains the leading cause of acute liver failure in the U.S. This session will review methods that are used by clinical and regulatory scientists to gather information about the hepatotoxicity of a drug or biological agent, during each phase of its life cycle.  The session will highlight the diverse clinical signatures and mechanisms that underlie DILI and discuss critical challenges when analyzing drug-related risk for serious liver toxicity.

Robert J. Fontana

Mark I. Avigan

Components visible upon registration.